FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

Biofrontera sNDA Seeks Expanded Ameluz Use

FDA accepts for review a Biofrontera supplemental NDA seeking to expand the label of its photodynamic therapy drug Ameluz (aminolevulinic acid hydroch...

latest-news-card-1
Human Drugs

Draft Guide on Medical Gases

FDA posts a draft guidance entitled Certification Process for Designated Medical Gases.

latest-news-card-1
Human Drugs

FDA Hits Tremfya TV Ad as False or Misleading

The CDER Office of Prescription Drug Promotion cautions Janssen Biotech about a direct-to-consumer TV ad for Tremfya that misleadingly overstates the ...

latest-news-card-1
Biologics

CBER Head Overruled Staff on Moderna Flu Vaccine Filing

CBER director Vinay Prasad overrules the Centers career reviewers in deciding to issue Moderna a refusal-to-file letter for its BLA for an influenza v...

latest-news-card-1
Human Drugs

FDA Not Serious About Mifepristone Review: GOP Senators

Politico says some GOP senators expressed frustration with FDA over a lack of apparent progress on its supposed safety review of the abortion drug mif...

latest-news-card-1
Medical Devices

Issues with AI-Enhanced Surgical Devices Cited

A detailed Reuters report looks at instances of surgical adverse events that may be related to artificial technology-enhanced medical devices being us...

latest-news-card-1
Medical Devices

FDA OKs Novocures Optune Pax for Advanced Pancreatic Cancer

FDA approves Novocures Optune Pax for use in combination with gemcitabine and nab-paclitaxel for adults with locally advanced pancreatic cancer.

latest-news-card-1
Human Drugs

FDA Hits Sobis Vonjo TV Ad as Misleading

FDA sends Sobi Inc. an untitled letter that cites a direct-to-consumer television advertisement for its myelofibrosis drug Vonjo (pacritinib) because ...

latest-news-card-1
Human Drugs

Repeat CGMP Violations at Signature Formulations

FDA warns Phoenix, AZ-based Signature Formulations about repeat CGMP violations in its manufacturing of finished drugs as a contract facility.

latest-news-card-1
Biologics

Aseptic Processing/Documentation Failures at Lonza Cell Therapy Facility

FDA cites Lonza Portsmouth for significant manufacturing and quality control deficiencies at its cell therapy facility where Vertex Pharmaceuticals an...